Budesonide (Rhinocort, Pulmicort, Entocort) is a corticosteroid available as a nasal spray for allergic rhinitis, an inhaler for asthma maintenance, and oral capsules for Crohn's disease and ulcerative colitis. It works by binding glucocorticoid receptors and suppressing inflammatory gene transcription, with high first-pass hepatic metabolism that minimizes systemic steroid exposure. Common side effects include nosebleeds, throat irritation, and oral thrush (inhaled formulation). It is the preferred inhaled corticosteroid during pregnancy, and grapefruit juice must be avoided with oral formulations due to CYP3A4 inhibition.
Budesonide
Uses & FDA Indications
Budesonide is a versatile corticosteroid approved across multiple routes of administration, making it one of the most widely used anti-inflammatory medications. As a nasal spray (Rhinocort), it treats seasonal and perennial allergic rhinitis. As an inhaled formulation (Pulmicort), it is a first-line preventer for asthma maintenance in both adults and children as young as 12 months (nebulizer) or 6 years (inhaler).
Oral budesonide formulations exploit the drug's extensive first-pass hepatic metabolism to deliver high local concentrations in the gut with relatively low systemic exposure. Entocort EC (extended-release capsules) is approved for mild-to-moderate active Crohn's disease affecting the ileum and ascending colon, and for maintenance of remission. Uceris (extended-release tablets) treats mild-to-moderate active ulcerative colitis.
- Allergic rhinitis — seasonal and perennial (nasal spray)
- Asthma maintenance and prevention (inhaled)
- Mild-to-moderate Crohn's disease (oral EC capsules)
- Ulcerative colitis (oral extended-release tablet)
- Autoimmune hepatitis (off-label in some guidelines)
- Eosinophilic esophagitis (off-label; viscous slurry formulation)
How It Works
Budesonide binds to cytoplasmic glucocorticoid receptors with high affinity — approximately 195 times greater than cortisol. The budesonide-receptor complex enters the nucleus and modulates transcription, downregulating genes that encode inflammatory mediators (IL-4, IL-5, IL-13, TNF-α) while upregulating anti-inflammatory proteins. This broadly suppresses the eosinophilic and lymphocytic infiltration that drives asthma, rhinitis, and inflammatory bowel disease.
A key pharmacological feature of budesonide is its high first-pass hepatic metabolism (approximately 90%). This means oral formulations designed to release drug in the gut provide local mucosal therapy while limiting systemic steroid exposure — a property that gives it a favorable safety profile relative to older systemic steroids for gastrointestinal indications.
Budesonide is the preferred inhaled corticosteroid during pregnancy because safety data from large registries have not shown increased risk of fetal malformations at labeled doses — making it the most studied inhaled steroid in this population.
Side Effects
Common
- Nosebleeds and nasal irritation (nasal spray)
- Throat irritation, hoarseness, dysphonia (inhaled)
- Oral candidiasis / thrush (inhaled — rinse mouth after each use)
- Cough
- Headache
- Nausea, diarrhea, abdominal pain (oral formulations)
- Upper respiratory tract infections
Serious
- HPA axis suppression (more likely with higher exposures or long duration)
- Adrenal insufficiency if abruptly discontinued after prolonged use
- Growth retardation in children on long-term inhaled therapy
- Increased susceptibility to infections; avoid live vaccines during immunosuppressive courses
- Osteoporosis with prolonged systemic exposure (oral formulations)
- Glaucoma and cataracts with long-term use
- Paradoxical bronchospasm (inhaled)
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) | Dramatically increase budesonide plasma levels; risk of systemic corticosteroid toxicity and Cushing's syndrome | High — avoid combination or use with extreme caution |
| Moderate CYP3A4 inhibitors (erythromycin, fluconazole, diltiazem) | Moderate increase in budesonide exposure | Moderate — monitor for steroid excess symptoms |
| CYP3A4 inducers (rifampin, carbamazepine, phenytoin) | Reduce budesonide plasma concentrations, potentially decreasing efficacy | Moderate — may need therapeutic reassessment |
| Other corticosteroids (oral prednisone) | Additive HPA axis suppression | Moderate — avoid unnecessary combinations |
| Long-acting beta-agonists (formoterol) | Synergistic bronchodilation and anti-inflammatory effects in asthma/COPD (Symbicort) | Beneficial — standard combination |
| Antacids / proton pump inhibitors | May alter release of oral extended-release formulations if capsules are opened | Low–Moderate — swallow capsules whole |
| Cyclosporine | Possible increased budesonide exposure via CYP3A4 inhibition | Moderate — monitor clinically |
Warnings & Contraindications
⚠ Not for acute asthma attacks — use a short-acting bronchodilator (albuterol) for rescue. ⚠ Do not stop oral budesonide abruptly after prolonged courses — taper under medical supervision. ⚠ Live vaccines should be avoided during immunosuppressive courses of oral budesonide.
- Contraindicated: Hypersensitivity to budesonide; acute bronchospasm (inhaled); systemic fungal infections (oral)
- Infections: Use with caution in patients with active TB, viral, bacterial, or fungal infections; budesonide can mask infection signs
- Transitioning from oral steroids: Patients being weaned from systemic corticosteroids to inhaled budesonide are at risk of adrenal insufficiency; monitor carefully
- Pediatric growth: Monitor height in children on long-term inhaled therapy; use lowest effective exposure
- Oral EC capsules: Swallow capsules whole — do not chew or crush, as this will alter drug release characteristics
Frequently Asked Questions
Is budesonide a steroid? Will it cause steroid side effects?
Yes, budesonide is a corticosteroid. However, its routes of delivery (nasal, inhaled, or targeted oral release in the gut) are designed to minimize systemic exposure. When used as directed for nasal or inhaled indications, the risk of classic systemic steroid side effects — such as weight gain, elevated blood sugar, or bone thinning — is substantially lower than with oral prednisone. Oral budesonide formulations (Entocort, Uceris) also have reduced systemic effects due to extensive first-pass liver metabolism, though they are not entirely free of systemic risk at higher exposures or with long-term use.
Why is budesonide preferred over other inhaled steroids during pregnancy?
Budesonide (Pulmicort) has the most robust human safety data of any inhaled corticosteroid in pregnancy, derived from large Swedish registry studies involving thousands of pregnancies. These data have not demonstrated increased rates of congenital malformations. Uncontrolled asthma poses significant risks to the mother and fetus, so maintaining effective controller therapy during pregnancy is considered more beneficial than the theoretical risks of inhaled steroid exposure.
Can I drink grapefruit juice while taking Entocort?
Grapefruit and grapefruit juice are strong inhibitors of intestinal CYP3A4, the enzyme primarily responsible for budesonide metabolism. Consuming them while taking oral budesonide can significantly increase systemic steroid exposure, raising the risk of adrenal suppression and Cushing's syndrome. Grapefruit products should be avoided during oral budesonide therapy.
What is the difference between Pulmicort and Rhinocort?
Both contain budesonide but are formulated for different delivery routes. Rhinocort is a nasal spray that delivers the drug to the nasal mucosa, targeting rhinitis symptoms such as congestion, runny nose, and sneezing. Pulmicort (Flexhaler or Respules) is an inhaled formulation delivered to the bronchial airways to prevent asthma symptoms. They are not interchangeable.
Not sure which pill you have? Identify it by imprint, color, or shape.
Use the PillID Identifier →